Isoform-specific signaling of Akt, a major signaling hub and a prominent therapeutic target, remained poorly defined until recently. Subcellular distribution, tissue-specific expression, substrate specificity, and posttranslational modifications are believed to underlie isoform-specific signaling of Akt. The studies reported here show inhibition of Akt2 activity under physiologically relevant conditions of oxidation created by PDGF-induced reactive oxygen species. Combined MS and functional assays identified Cys124 located in the linker region between the N-terminal pleckstrin homology domain and the catalytic kinase domain as one of the unique regulatory redox sites in Akt2 with functional consequence on PDGF-stimulated glucose uptake. A model is proposed describing the consequence of increased endogenous oxidation induced by extracellular cues such as PDGF on Akt2 activity.
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disulfide | receptor tyrosine kinase | DCF | DCP-Bio1 P KB/Akt is a major signaling hub between cytokine, growth factor, and integrin signaling pathways of consequence to many biological processes. Energy storage, protein synthesis, cell survival and growth, cell cycle progression, and cell death are differentially regulated by the three known isoforms of Akt kinase: Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ (1) . Although the molecular features underlying isoform-specific functional predominance are largely unknown, hypotheses to explain Akt isoform specificity include selective interactions with substrates and/ or binding partners, tissue specificity, subcellular location, and temporal changes in activation profiles of Akt isoforms (2) . Posttranslational modifications may contribute to this isoform-specific signaling, but reports of modifications are lacking.
Reactive oxygen species (ROS) are integral to cytokine and growth factor signaling; ROS generation in response to these extracellular cues is well documented (3) . Earlier reports, in particular from Sundaresan et al. (4) , showed ROS generation in response to PDGF stimulation of vascular smooth muscle cells and suggested that H 2 O 2 can relay redox signals to regulate physiological signaling in response to growth factors. More recently, it has been shown that PrxI phosphorylation at Y194 by Src family tyrosine kinases inhibited PrxI and resulted in H 2 O 2 accumulation at the cellular membrane where receptor tyrosine kinase activation occurs (5) . Unanswered questions include which proteins are oxidized by receptor tyrosine kinase-induced ROS, which specific cysteine site(s) undergo oxidation, and the consequence of oxidation on activity of these proteins and propagation of receptor tyrosine kinase signaling. Recently, the synthesis of several dimedone-based chemoselective reagents capable of specific labeling of sulfenic acid oxidized proteins was reported; these reagents allow for specific enrichment and identification of oxidized proteins (6) (7) (8) (9) (10) . In this study, we used a biotin-tagged 1,3-cyclohexadione derivative, DCP-Bio1 (Fig. 1A) , to investigate isoform-specific effects of PDGF-induced ROS on Akt1, Akt2, and Akt3 kinase activities. We report selective down-regulation of Akt2 kinase activity by PDGF-induced oxidation, with implications for molecular and cellular functions controlled by PDGF.
Specifically, we found that (i) PDGF-induced ROS inhibited Akt2 kinase activity (estimated extent of PDGF-induced oxidation of Akt2 is 45-66%); (ii) Cys124 in Akt2 is a cysteine residue targeted by oxidation and at least partly responsible for inhibition of Akt2 activity; (iii) adding H 2 O 2 to NIH 3T3 cells induces indiscriminate activation of Akt1 and Akt2 through phosphorylation; however, intracellular accumulation of H 2 O 2 results in isoform-specific down-regulation of Akt2 activity through oxidation; and (iv) a functional relationship exists between PDGF-dependent redox regulation of Akt2 and physiological outputs such as PDGFinduced glucose uptake.
Results and Discussion PDGF-Stimulated ROS Induces Oxidation of PLCγ1 and Akt2. NIH 3T3 cells stimulated with PDGF were lysed in the presence of DCPBio1 (Materials and Methods). DCP-Bio1 labeling of cellular proteins increased within 5 min of PDGF stimulation, comparable to labeling in H 2 O 2 -treated NIH 3T3 cells (Fig. 1B and Fig. S1A ). In our preliminary MS experiments using DCP-Bio1 labeled cell lysates of NIH 3T3 cells stimulated with PDGF, we found several signaling proteins oxidized by PDGF stimulation. These included PLCγ1 and Akt2, both well-known mediators of PDGF signaling. Redox sensitivity of PLCγ1 was reported in PC12 cells stimulated with dopamine (11) . Western blot analysis of streptavidin-agarose pull-down samples from PDGF-stimulated cells lysed in the presence of DCP-Bio1 showed increased PLCγ1 oxidation with PDGF stimulation compared with unstimulated control (Fig.  S1B ). For Akt2, the peptide identified by MS contained a cysteine site (Cys124) labeled by DCP-Bio1. Although the correlation factor for assignment of oxidation site in Akt2 was low (Xcorr 2.05, z +2), we decided to further examine the potential regulatory function of Akt2 oxidation on PDGF signaling.
The Akt isoforms share structural features: the N-terminal pleckstrin homology (PH) domain, a flexible linker region connecting the PH and catalytic kinase domains, and a C-terminal regulatory tail. The PH and kinase domains are largely conserved in the Akt isoforms while the linker region has the lowest percent identity among Akt isoforms (46% vs. 80% and 90% for PH and kinase domains, respectively) (12) . Cys124 is located in this linker region and is conserved in mice and humans. It is not conserved in Akt1 and Akt3, although Akt3 contains a cysteine residue Cys119 in this region. Sequence alignment using BLAST (National Center for Biotechnology Information) of the linker regions suggests that Cys124 in Akt2 (Uniprot accession no. Q60823) aligns with Ser122 in Akt1 (Uniprot accession no. P31750) and Pro121 in Akt3 (Uniprot accession no. Q9Y243) (Fig. 1C) . A recent large-scale phosphoproteomics study of mouse liver reported Akt1 phosphorylation at several serine sites (Ser124, Ser126, and Ser129) in the linker region of this Akt isoform, but the functional consequences on Akt1 signaling were not reported (13) . These findings motivated new studies to elucidate how oxidation regulates Akt isoforms and the role of Cys124 in the redox response of Akt2. Confirmatory Western blot analysis was done to monitor labeling of oxidized Akt2 by DCP-Bio1 in NIH 3T3 cells stimulated with PDGF. Cells were lysed in the presence of DCPBio1 at different times of PDGF stimulation. DCP-Bio1-labeled proteins were enriched using streptavidin-agarose affinity capture and probed for Akt1, Akt2, or Akt3 proteins using isoformspecific antibodies. We found statistically significant increases in incorporation of DCP-Bio1 label in Akt2 in response to PDGF stimulation (Fig. 1D) . Akt1 or Akt3 were not labeled by DCPBio1 (Fig. 1E) .
One criterion for a posttranslational modification to function as a signaling event is reversibility (e.g., phosphorylation/dephosphorylation). Two experiments were performed to address reversibility of Akt2 oxidation in response to PDGF stimulation. First, PDGF stimulation time was extended to 120 min; Akt2 oxidation peaked at 30 min, then gradually decreased at 60 and 120 min (Fig. 1F, Upper) . In the second experiment, fresh media without PDGF was introduced after 30 min of PDGF treatment, and Akt2 oxidation was monitored at 30 min and 90 min after PDGF removal. Oxidation returned to basal levels after 90 min incubation without PDGF (Fig. 1F, Lower) . Pretreatment with ROS-reducing agents (N-acetyl cysteine and PEG-catalase) blocked both PDGF-induced oxidation and inhibition of Akt2 activity (Fig. S2A) , supporting the reversibility of PDGF-induced oxidation of Akt2.
To avoid postlysis oxidation, we used lysis buffer supplemented with catalase (200 U/mL) (14) . Evidence that oxidation was not due to postlysis events is depicted in Fig. 1D and Fig. S3 A and B, which show (i) significantly increased DCP-Bio1 incorporation with increasing PDGF stimulation time; (ii) a similar time course of Akt2 labeling by DCP-Bio1 in response to PDGF using degassed lysis buffer at pH 5.5 (Fig. S3A) ; and (iii) lack of Akt2 labeling by DCP-Bio1 when recombinant Akt2 was spiked in lysis buffer (Fig. S3B ).
Redox Regulation of Akt2 Kinase Activity. Oxidation of critical cysteines in various signaling proteins is considered an important posttranslational regulatory event of signaling. For example, oxidation of a cysteine residue in PKA decreased PKA activity by promoting dephosphorylation at the proximal Thr197 site. On the other hand, cysteine oxidation of another member of the AGC family of kinases, PKCδ, positively affected its activity (15) . More recently, MKK6 oxidation was linked to disulfide bond formation and inhibition of ATP binding (16) , whereas ataxia telangiectasia mutated (ATM) oxidation promoted the active dimer state and increased activity of this protein (17) . Previous studies have also established Akt as a redox-sensitive protein and showed that adding oxidants such as H 2 O 2 to cells activates Akt by enhancing phosphorylation at the Thr308/9 and Ser473/4 sites (18) (19) (20) , leading to the typical perception of ROS as an activator of Akt. However, Akt activation in response to such oxidation could be the indirect result of several mechanisms, such as oxidative inactivation of phosphatase and tensin homolog (PTEN), ligandindependent dimerization of receptor tyrosine kinases, oxidative inactivation of protein tyrosine phosphatases, and loss of feedback inhibition via MAPKs (3).
To determine whether direct oxidation has activating or inhibitory consequences on Akt1, Akt2, or Akt3, we conducted experiments to monitor how oxidation affects their ability to phosphorylate GSK-3α/β, a known substrate of Akt proteins. Experiments using recombinant active isoforms showed markedly increased redox sensitivity of Akt2 vs. Akt1 and Akt3 (Fig. 2 A-C) . We identified the redox-sensitive cysteine(s) in Akt2 by oxidizing recombinant active Akt2 with H 2 O 2 in the presence of dimedone, another cysteine sulfenic acid specific reagent, and the parent compound of DCP-Bio1. The oxidized product was analyzed by MS to identify the site(s) of cysteine oxidation on the basis of dimedone labeling. We confirmed oxidation at Cys124 in the linker domain and identified oxidation at Cys297 and Cys311 sites in the kinase domain of Akt2 (Fig. 3 A-C) . The cysteines corresponding to Cys297 and Cys311 in Akt2 are conserved in all three Akt isoforms. Experiments using recombinant Akt1 and Akt3 oxidized by H 2 O 2 in the presence or absence of dimedone confirmed a disulfide bond between these sites in both proteins and dimedone labeling of Cys296 in Akt1 (Fig. S4 A-E) . Cys119 in the linker domain of Akt3 was not labeled by dimedone and not found in the disulfide bond with either Cys293 or Cys307 in the kinase domain of Akt3. Carbamidomethylated Cys119 tryptic peptide (generated by iodoacetamide after H 2 O 2 treatment) was highly abundant, suggesting a true lack of oxidation (Fig. S4F) . These results along with the data above ( Fig. 2A) showed that Lysates from PDGF-stimulated NIH 3T3 cells were used to capture DCPBio1-labeled proteins and probed for Akt1, Akt2, and Akt3 using isoformspecific antibodies (cell lysates are included as controls). (F) Akt2 oxidation is PDGF-dependent and reversible, decreasing with prolonged PDGF stimulation. Lysates from PDGF-stimulated NIH 3T3 cells were used to capture DCPBio1-labeled proteins and probed for Akt2. Lower: Two additional controls were used in which cells were treated with PDGF alone for the first 30 min and then incubated further for 30 and 90 min without PDGF. Additionally, biotinylated AhpC was added to the normalized lysates (1 μg AhpC/500 μg protein) as an internal control before affinity capture and probed for AhpC.
disulfide formation between the Cys296/293 and Cys310/307 sites in Akt1 and Akt3, respectively, does not significantly alter their kinase activity. Murata et al. (21) have shown that prolonged exposure of cardiac H9c2 cells to exogenous H 2 O 2 leads to formation of an intramolecular disulfide bond between the conserved cysteines (Cys296/297 and Cys310/311) within the kinase domain of Akt (Fig. 1C) . Using site-directed mutagenesis of these cysteine sites in Akt1, they showed that an intramolecular disulfide bond targets Akt proteins to ubiquitin-proteasome coordinated degradation. The functional consequence of oxidation on specific Akt isoforms was not reported, and additionally, protein degradation was observed at >30 min exposure to 100 μM H 2 O 2 (21) .
Mechanistically, oxidation of redox-sensitive kinases can alter activity by glutathionylation, inter-or intramolecular disulfide bond formation, formation of higher oxidation species (-SO 2 ; -SO 3 ), and structural modification promoting phosphorylation/ dephosphorylation and/or protein degradation (15) . To determine whether catalytic decline in Akt2 activity after oxidation is due to an intermolecular disulfide bond between the Akt2 monomers, the kinase assay was performed under oxidizing conditions and reaction components were separated on nonreducing SDS/PAGE (Fig. S5A) . Inhibition of Akt2 activity by oxidation cannot be attributed to formation of intermolecular disulfides (dimer state) (Fig. S5A) . Glutathionylation was not responsible for Akt2 inhibition, because glutathione was not in the reaction mixture. Glutathione may play a protective role in cells and protect Akt2 against oxidation at key cysteine sites; attempts to monitor Akt2 glutathionylation in NIH 3T3 cells stimulated with PDGF were inconclusive owing to the poor quality of the antiglutathione antibodies and inadequate signal in the MS analysis (perhaps due to low or lack of glutathionylation). Overoxidation to Cys-SO 2/3 H species or other oxidation events (Met/Trp oxidation, Tyr/Trp nitration) was ruled out by experiments described in Fig. S5B , which show recovery of Akt2 kinase activity by tris(2-carboxyethyl)phosphine (TCEP) reduction after adding H 2 O 2 to recombinant active Akt2. PDGF-stimulated cells in the presence of 3-aminotriazole (3-AT) showed similar results (Fig. S6C) . Hyperoxidation of cysteines, Met/Trp oxidation, or Tyr/Trp nitration are not TCEP-reversible events and so cannot account for reduced Akt2 kinase activity. These results cumulatively point to formation of intramolecular disulfide bond(s) as responsible for the effects of oxidation on Akt2 activity. MS data from dimedone labeling and Akt2 oxidation experiments (Fig. 3 A-C and Fig.  S5D ) pointed to Cys124-Cys297 and Cys124-Cys311 as potential intramolecular disulfides responsible for Akt2 inhibition by oxidation. These results are consistent with resistance to oxidation in the Cys124Ser Akt2 mutant (Fig. 3D) , Cys297Ser, and Cys311Ser Akt2 mutants (Fig. 3E) . Akt3, which contains a cysteine site in the linker region (Cys119), was not redox sensitive ( Fig. 2A) . To further investigate lack of redox sensitivity of Akt1, Ser122 in Akt1 was mutated to cysteine. WT and Ser122Cys Akt1 were transfected in NIH 3T3 cells and stimulated with PDGF in the absence or presence of 3-AT. Decreased kinase activity of these proteins was not observed (Fig. S5C) . Together, these data showed that the presence of a cysteine in the linker region alone is not sufficient for inducing redox sensitivity in Akt isoforms. Other structural elements are needed to transform this cysteine into a hyperactive site. (Fig. S7A) . Previous studies also showed that 3-AT treatment causes the catalase to form insoluble aggregates, thus decreasing soluble protein (22) . The consequence of 3-AT treatment on the extent of protein oxidation in cells treated or not with PDGF was monitored using lysis buffer supplemented with DCP-Bio1 (Fig. S7B ). As expected, decreased level/activity of catalase correlated with increased oxidized, DCPBio1-labeled proteins. Cellular treatment with increasing concentrations of H 2 O 2 resulted in increased phosphorylation of Akt1 and Akt2 at the Thr308/9 phosphosite reflected in increased catalysis of their substrate GSK-3α/β phosphorylation (Fig. 2D) . [Phosphorylation at Thr308 site in Akt2 is a representative of Akt2 phosphorylation status. Phosphorylation at Ser473 was also monitored for a number of studies (Fig. S8) . No notable differences in phosphorylation at the two sites under all tested conditions were observed.] This observation corroborates others showing that oxidation increases Akt phosphorylation because of other contributing events, not direct Akt2 oxidation (3). In contrast, inhibition of cellular catalase by 3-AT led to oxidative inactivation of Akt2 kinase in an isoform-specific manner without affecting PDGF-stimulated phosphorylation at the activating phosphosite residues (Fig. 2E ). This observation mirrored previous in vitro kinase assays linking oxidation to inhibition ( Fig. 2 A-C), consistent with the degree of oxidation induced by pretreatment with 3-AT (Fig. S7B ). In contrast, pretreatment of cells with N-acetyl cysteine or PEGcatalase to reduce accumulation of ROS increased Akt2 activity 1.8-to 3.2-fold when cells were stimulated with PDGF (Fig. S2A) . Additionally, chemical inhibition of two ROS sources activated by PDGF, NADPH oxidase, and mitochondrial electron transport chain (ETC), using VAS2870 and rotenone (mitochondrial complex I inhibitor), respectively, showed an activating effect on Akt2 activity (Fig. S2B ). More recently, Katsuyama et al. (23) showed that PDGF-induced NOX expression depends on the mitochondrial ETC, and rotenone suppressed induction of NOX1 mRNA. The stronger effect of rotenone on Akt2 activity is consistent with this notion. To determine whether these observations stemmed from PDGF-induced oxidation at Cys124, this cysteine site was mutated to serine and the Cys124Ser myr-Akt2 mutant was expressed in NIH 3T3 fibroblasts alongside a control using the WT myr-Akt2 construct. The WT myr-Akt2 and Cys124Ser mutants were immunoprecipitated from cell lysates and subjected to in vitro oxidation with H 2 O 2 . H 2 O 2 treatment caused significantly less Akt2 activity relative to the Cys124Ser Akt2 mutant, proving that the Cys124 site is a major redox-sensitive site involved in regulating Akt2 kinase activity ( Fig. 3D ) (Western blots of a biological replicate are shown in Fig. S6A ). Control experiments (Fig. S6B) showed similar kinase activities and sensitivities to oxidation for endogenous WT Akt2 and WT myr-Akt2 constructs; PDGF-and 3-AT-dependent oxidation of both constructs was recovered by TCEP treatment (Fig. S6C ).
PDGF-Induced Oxidation Allows Distinct Regulation of Akt Kinase
Isoforms. Regulation of Akt2 activity by oxidation under physiological conditions of PDGF-stimulated ROS indicates that PDGF, and perhaps other ROS-inducing growth factors, use oxidation to adjust timing and/or amplitude of signaling events relayed through redox-sensitive signaling proteins. Indeed, when TCEP recovery assay was performed for Akt2 immunoprecipitates obtained from differentiated C2C12 myotubes that were stimulated with PDGF, insulin, or TNF-α for 30 min, PDGF-and TNF-α-treated samples both showed increased Akt2 activity, whereas activity was unchanged for the insulin-treated samples with or without TCEP (Fig. S9A ). Time course data for TNF-α−induced DCP-Bio1 labeling of Akt2 is included in Fig. S9A (Lower). Insulin-induced ROS was shown to be important for differentiation of myoblasts into myotubes (24) (25) (26) . In accordance with these studies, insulin treatment induced Akt2 oxidation and decreased Akt2 activity in myoblasts, unlike the results in myotubes (Fig. S9B) .
To quantify the effect of PDGF-induced oxidation on Akt2 activity, the catalytic activity of immunoprecipitated Akt2 from lysates of PDGF-stimulated cells was determined with or without TCEP. A kinetic lag was observed in GSK-3α/β phosphorylation by Akt2 without TCEP, which was reversed by addition of TCEP to reaction mixture ( Fig. 4 A and B) . A side-by-side comparison of the effect of TCEP on Akt2 and Akt1 activities showed a significantly greater Akt2 activation (3.1-fold) than Akt1 (1.3-fold) (Fig.  4B , Right). The small effect of TCEP on Akt1 activity could be due to the reduction of the Cys296/310 disulfide bond, as reported earlier (21) . These data suggest that PDGF-induced ROS decreases Akt2 activity by ≈66% on the basis of initial rates of GSK-3α/β phosphorylation (−TCEP: 9.7 min
; +TCEP: 28.25 min −1 ). Correcting for non-PDGF-induced oxidation which, according to the data in Fig. 1D , has an upper limit of ≈30% of total oxidized Akt2, PDGF-driven Akt2 oxidation comprises ≈45% of total active phosphorylated Akt2. To further investigate the functional consequence of the Cys124Ser mutation in Akt2, we monitored its effect on substrate phosphorylation and PDGF-induced glucose uptake. Akt2 knockout mouse embryonic fibroblasts (Akt2KO MEFs) were transduced with WT or Cys124Ser myc-Akt2 using retroviral infection as described earlier and stimulated with PDGF with or without 3-AT (27) . 3-AT treatment of Akt2KO MEFs transduced with WT and Cys124Ser Akt2 mutant resulted in decreased WT Akt2 activity (Fig. 3F) , whereas Cys124Ser Akt2 activity was unperturbed by oxidation. These data further confirm that Cys124 is involved in regulating redox sensitivity of Akt2 in cells. These results are consistent with the glucose uptake studies in Akt2KO MEFs, performed under the same experimental conditions (Fig. 4C) . Glucose uptake was significantly inhibited by 3-AT in Akt2KO MEFs infected with WT myc-Akt2 but not Cys124Ser myc-Akt2 retroviral constructs. The effect of 3-AT on insulin-stimulated glucose uptake in WT or Cys124Ser Akt2KO MEFs was not statistically significant. There was no detectable difference in AS160, FOXO 1/3a, and GSK-3α/β phosphorylation between Akt2KO MEFs and cells transduced with WT or Cys124Ser Akt2 (Fig. S9C) . These results emphasize that signaling events that link Akt2 activation and glucose uptake are incompletely understood. AS160, originally identified as an Akt2-specific substrate that regulates trafficking of glucose transporters, is also the target of kinases such as AMP-activated protein kinase (AMPK) among several other unknown enzymes (28, 29) , thereby adding to the ambiguity of the Akt2-specific targets in glucose uptake. GSK-3α/β and FOXO 1/3a proteins are non-isoform-specific Akt substrates (and substrates for other kinases).
Based on the cumulative results included here, a model is proposed to describe effects of PDGF-induced ROS on Akt2 signaling. Depending on the relative timing of oxidation and phosphorylation, the following simplified scenarios may occur with consequences on the amplitude/timing of signaling through Akt2: (i) Akt2 could undergo phosphorylation by upstream kinases before its activity is muted by oxidation (Fig. 4D, blue path) , and (ii) phosphorylation of Akt2 by upstream kinases and Akt2 oxidation by PDGF-induced ROS occur in parallel (Fig. 4D, red path) . Akt2 activity would be the net result of oxidation and phosphorylation. In the first case, a burst in activity will be observed before the oxidation event attenuates or completely reduces Akt2 activity. In the second scenario, an activity burst would not occur and Akt2 activity would be lower, resulting in lower amplitude of signaling events mediated by this kinase. Western blot data ( Fig. 4D and Fig. S9D ) show parallel increases in oxidation and phosphorylation of signaling proteins, including Akt2, in response to PDGF stimulation. These findings support a two-state (on/off) model of Akt2 activation by phosphorylation, with oxidation determining the amplitude of signaling event that occurs at Akt2. On the other hand, PDGF-induced oxidation is not expected to regulate Akt1 activity, suggesting that spatial distribution, tissue-specific expression, and other components are more critical in regulating Akt1 signaling.
Summary. These studies indicate that PDGF and other ROSinducing stimuli inhibit Akt2 signaling under physiological conditions, with functional consequence on molecular and cellular processes induced by these stimuli. In addition, these studies highlight the importance of the ROS source and localization when oxidative effects on a biological system are investigated. Phosphorylation of a signaling protein does not necessarily translate into protein activity, although it is often equated with activity. Rather, other "silent" or unrecognized posttranslational modifications can modulate the activity or substrate specificity of signaling proteins in complex ways.
Materials and Methods
See SI Materials and Methods for detailed protocols.
Cell Culture, Cloning Procedures for WT and Cys124Ser Akt2, Transfection of NIH 3T3 Cells, and Activity Assays. NIH 3T3 cells were cultured in the complete DMEM High Glucose (Invitrogen) medium. Confluent cells were serum starved for 16 h and stimulated the next day with PDGF-BB (20 ng/mL) at 37°C for the indicated time points. The collected lysates were normalized, and Akt2 was immunoprecipitated for assaying activity. pEF6/V5-His TOPO construct of WT myr-Akt2 created by subcloning was used for generating Cys124Ser mutation by site-directed mutagenesis (SDM kit; Stratagene) with the following primers: forward 5′-CATGGACTACAAGTCTGGCTCCCCCAGTG-3′ and reverse 5′-CACTGGGGGAGCCAGACTTGTAGTCCATG-3′. These constructs were transfected in NIH 3T3 cells using lipofectamine 2000 (Invitrogen) and selected using blasticidin (6 μg/mL). After PDGF stimulation and lysis, normalized lysates were used to pull down WT and Cys124Ser myr-Akt2 proteins with V5 antibody for in vitro oxidation and activity assays.
Transfection of 293-T and Retroviral Infection of Akt2 Knockout MEFs. Briefly 293-T cells were transfected when 30-40% confluent with 6 μg DNA of WT or Cys124Ser Akt2 cloned in pMIGR2 using FuGENE-6. Akt2 knockout MEFs were infected twice with viral supernatant harvested and filtered from 24 and 48 h of 293-T transfection. Infection efficiencies were assessed by Western blot detection of Akt2 expression. Affinity Capture of DCP-Bio1 Labeled Proteins. PDGF-stimulated NIH 3T3 lysates were incubated overnight at 4°C with 20-100 μL streptavidin-agarose conjugate (Invitrogen). The next day, after washes, the DCP-Bio1-labeled proteins were eluted by heating at 100°C for 10 min. The samples were then probed for Akt2 by Western blotting. NIH 3T3 cells were cultured in a complete medium of DMEM High Glucose (Invitrogen) supplemented with 10% FCS (Invitrogen) and 1% penicillin and streptomycin (Invitrogen). Cells were starved for 16 h in serum-free media and stimulated with PDGF-BB (20 ng/mL) at 37°C for the time points indicated in each experiment. The zero time point was collected in the absence of PDGF-BB.
Cloning procedures for WT and Cys124Ser myr-Akt2 and transfection of NIH 3T3 cells. HumanWT myr-Akt2gene (obtainedthroughAddgene; Plasmid repository no. 9016) in pcDNA3 vector was subcloned into pEF6/V5-His TOPO vector using pEF6/V5-His TOPO TA expression kit (Invitrogen). This construct was further used to create Cys124Ser mutation by site-directed mutagenesis (SDM kit, Stratagene) according to the manufacturer's protocol and using the following primers: forward 5′-CATGGACTACAAGTCTGGCT-CCCCCAGTG-3′ and reverse 5′-CACTGGGGGAGCCAGACT-TGTAGTCCATG-3′. These constructs were transfected in NIH 3T3 cells using a standard Lipofectamine 2000-based procedure (Invitrogen), and the transfectants were selected with blasticidin (6 μg/mL). Similar procedures were followed to generate and transfect in NIH 3T3 cells the Cys297Ser and Cys311Ser myr-Akt2 mutants, and WT myr-Akt1 and Ser122Cys myr-Akt1. Host plasmids and primers used to generate the mutations are summarized in Table S1 . C2C12 cells. C2C12 myoblasts were cultured in a complete medium of DMEM High Glucose (Invitrogen) supplemented with 10% FBS (Invitrogen) and 1% penicillin and streptomycin (Invitrogen). C2C12 myoblasts were then induced to differentiate into myotubes by changing the proliferation medium to DMEM with 2% FBS for 4 d. Myotubes were starved overnight in serum-free DMEM and were stimulated next day with PDGF (20 ng/mL), insulin (200 nM), or TNF-α (10 ng/mL) for 30 min. After stimulation, cells were lysed with lysis buffer [50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 25 mM NaF, 10 μM ZnCl 2 , protease, and phosphatase inhibitor tablets (Roche), pH 7.5] supplemented with catalase (200 U/mL). The resultant lysates were incubated on ice for 30 min followed by centrifugation at 10,000 × g for 10 min to obtain cell free extracts. Similar experiments were conducted in the undifferentiated C2C12 myoblasts. Akt2 was immunoprecipitated, and kinase assays were performed as described below (Kinase Assays, Kinase assay using immunoprecipitated Akt proteins).
Transfection of 293-T cells and retroviral infection of Akt2 knockout MEFs.
293-T cells were cultured in DMEM High Glucose (Invitrogen) media supplemented with 10% FBS (Invitrogen) on 10-cm culture dishes. Transfection was carried out after the cells were approximately 30-40% confluent. Briefly, 18 μL FuGENE-6 was added to antibiotics and serum-free DMEM so as to have a final volume of 250 μL after addition of DNA. Six micrograms of DNA (pMIGR constructs of murine WT myc-Akt2 and Cys124Ser myc-Akt2; Table S1 ) were added to the tube, and the mixture of FuGENE-6/ DNA was allowed to incubate for 20 min at room temperature. Medium from 293-T cells was aspirated, and 5 mL fresh antibiotics-free DMEM containing 10% FBS was added to the cells. The mixture of DNA/FuGENE-6 was gradually dropped on the cells. Fresh medium (3 to 4 mL) was added to the 293-T cells the following day. After 36 h, viral supernatant was harvested and filtered through a 0.45-μm syringe filter. For subsequent infection, polybrene (Santa Cruz) was added at a concentration of 8 μg/mL to the filtered supernatant. For infection, Akt2 knockout mouse embryonic fibroblasts (MEFs) were cultured in DMEM High Glucose (Invitrogen) supplemented with 10% FBS (Invitrogen) on 10-cm culture dishes. Once 40-50% confluent, medium was aspirated and replaced with the viral supernatant/polybrene mixture enough to cover the cells. Four to five h later fresh DMEM was added to feed the cells. A second round of infection of the MEFs was carried out using viral supernatant collected 48 h after transfection of 293-T. Infection efficiencies were assessed by Western detection of Akt2 expression. Conjugating antibodies to protein A-Sepharose beads. Isoform-specific Akt1, Akt2 antibodies (Cell Signaling nos. 2967, 3063), and V5 epitope antibody (Invitrogen) were conjugated to protein ASepharose beads using standard protocols. Briefly, 50 μL antibody was incubated with protein A-Sepharose beads (Zymed) on a nutator for 2 h at room temperature. After incubation the beads were sedimented at 2,000 rpm for 2 min, and the supernatant was discarded. The beads were washed twice with 1 mL sodium borate solution (0.2 M, pH 9.0) and then incubated with 1 mL freshly prepared dimethyl pimelimidate solution (5 mg/mL) on a nutator for 25 min at room temperature. After incubation, the beads were washed twice with 1 mL monoethanolamine solution (0.2 M, pH 8.0) and twice with 1× PBS. Finally, the beads were resuspended in 200 μL sterile PBS and stored at 4°C. Cross-linked slurry (10-20 μL) was typically added to 100 μg cell lysates for immunoprecipitation in all experiments. Induction of oxidation in NIH 3T3 cells. For exogenous treatment with H 2 O 2 , the NIH 3T3 cells were serum starved overnight. The following day cells were treated with H 2 O 2 (100 μM, 500 μM, and 1,000 μM) for 30 min at 37°C before PDGF-BB stimulation (20 ng/mL, 10 min). For endogenous increase in H 2 O 2 through catalase inhibition, NIH 3T3 cells were treated overnight with 10 mM 3-AT (3-amino-1,2,4 triazole; Sigma) in serum-free media and stimulated the following day with PDGF-BB (20 ng/mL, 10 min). Lysates from both experiments were normalized, and Akt1 and Akt2 proteins were immunoprecipitated using cross-linked Akt1 and Akt2 antibodies. Similar experiments were carried out to assess sensitivity of WT myr-Akt1 and Ser122Cys myr-Akt1 proteins to oxidation from lysates of PDGF-stimulated (20 ng/ mL, 10 min) and 3-AT (10 mM) treated NIH 3T3 transfectants using V5 antibody cross-linked to protein A-Sepharose. The kinase activity of immunoprecipitated Akt1 and Akt2 proteins was further assayed as described below under (Kinase Assays, Kinase assay using immunoprecipitated Akt proteins). Additionally, the lysates from 3-AT-treated cells were probed for expression of catalase using anti-catalase antibody (Santa Cruz).
Treatment of NIH 3T3 Cells with Antioxidative Reagents. Confluent NIH 3T3 cells were subjected to overnight serum-starvation in the presence of different concentrations of the mitochondrial electron transport chain (ETC) inhibitor rotenone (Sigma; 1-20 μM) and the antioxidant N-acetyl cysteine (Sigma; 5 and 20 mM). After addition of N-acetyl cysteine to the media, pH was readjusted to 7.5 before starving the cells. NOX inhibitor, VAS-2870 (5 μM; Enzo Life Sciences) and the antioxidant PEG-catalase (250-1,000 U/mL; Sigma) were added to the serum-starved NIH 3T3 cells 2 h before PDGF stimulation (20 ng/mL). Akt2 was immunoprecipitated from the normalized lysates and assayed for activity using GSK-3α/β substrate as described below (Kinase Assays, Kinase assay using immunoprecipitated Akt proteins).
Assessment of PDGF-Induced Oxidation of Cellular Proteome. Relative quantification of ROS in response to PDGF-BB stimulation of NIH 3T3 cells.
Subconfluent NIH 3T3 cells cultured in 60-mm dishes were serum starved overnight and assayed for reactive oxygen species (ROS) by imaging at different PDGF-BB (20 ng/mL) stimulation times using CM-H 2 DCFDA (DCF, 100 μM; Invitrogen). DCF was added for 10 min and incubated at room temperature before imaging for every time point of PDGF stimulation. The cells were rapidly washed twice with 1× PBS and visualized with Arcturus PixCell II laser capture microscope using 20× objective. Both fluorescence and corresponding phase images were collected from four random fields per stimulation, and quantification of the relative fluorescence intensity was done using ImageJ.
Affinity capture of DCP-Bio1 labeled proteins and monitoring of Akt2 labeling by DCP-Bio1. NIH 3T3 cells that were starved overnight were stimulated at 37°C with 20 ng/mL PDGF-BB (Calbiochem) for various time points or incubated for 10 min with 100 μM H 2 O 2 in starvation media or starvation media alone (control). The cells were quenched with 500 μL lysis buffer per 10-cm plate (50 mM Hepes, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 25 mM NaF, and 10 μM ZnCl 2 ) supplemented with 1 mM Na 3 VO 4 , PhosStop and cOmplete Protease Inhibitor Mixture tablets (Roche Diagnostics), DCPBio1 (250 μM to 1 mM), and catalase (200 U/mL). The cell lysate was then incubated on ice for 1 h, centrifuged, passed through a spin column (Bio-gel P6; Bio-Rad) equilibrated with same lysis buffer, and assayed for protein concentration using the Bio-Rad Protein Assay. For Western blot analyses, the lysates were normalized and incubated overnight at 4°C with 20-100 μL streptavidin-agarose conjugate (Invitrogen). In an additional experiment, PDGF-stimulated NIH 3T3 cells were lysed after indicated time points of stimulation using degassed lysis buffer (pH 5.5) to assess contribution of postlysis oxidation. The lysates were normalized and incubated with streptavidin-agarose conjugate as mentioned above. The next day the streptavidin-agarose beads were washed twice with 1× lysis buffer, and the DCPBio1-labeled proteins were eluted by heating the samples for 10 min at 100°C. To ensure that Akt2 pulldown was not due to interactions with other DCP-Bio1 or endogenously biotinylated proteins, control experiments were performed with additional washes before elution from the streptavidin-agarose beads as follows: one wash each with 2 M urea, 1 M NaCl, and 10 mM DTT (all reagents were made in 1× lysis buffer) followed by two washes with 1× lysis buffer. The samples were then separated by SDS/PAGE, transferred to nitrocellulose membrane, and probed with Akt1, Akt2, and Akt3 isoform-specific antibodies, and the pSer473/4 Akt1/2 antibody (Cell Signaling nos. 2967, 3063, and 9271). For the preliminary redox proteomics experiments that were aimed at identifying proteins and the hyperactive cysteine sites that are oxidized in response to PDGF, the same procedure was followed except the experiment was scaled up (starting material was 20 mg of PDGF-stimulated lysate), and various enrichment strategies were tested, including preenrichment in phosphoproteins (this resulted in the preliminary identification of PLCγ1) and postenrichment in DCP-Bio1-labeled peptides relative to the streptavidin enrichment step of DCP-Bio1-labeled proteins (this resulted in the identification of Cys124 Akt2 site).
FluoReporter assay for DCP-Bio1 incorporation. The FluoReporter assay kit from Invitrogen was used according to the manufacturer's instructions. For determining incorporation of biotin iodoacetamide (Biotin-IAA; Sigma) into total cysteine proteome of NIH 3T3 cells, the unstimulated cell lysate was first treated with 6 M urea for 15 min at room temperature followed by DTT (1 mM) for 30 min at 37°C. Biotin-IAA (10 mM) was added, and the sample was incubated on a shaker for 1 h at room temperature in the dark. For DCP-Bio1-labeled samples obtained as described above, unreacted DCP-Bio1 and other small molecules present in the samples were first removed using a Bio-Gel P6 spin column. The cell lysates thus processed were digested with protease type XIV from Streptomyces griseus provided in the kit at 37°C overnight on a shaker. Biocytin (0-80 pmol) was used to generate a standard curve. Each lysate and biocytin sample (50 μL) was incubated with 50 μL of Biotective Green reagent in a 96-well plate for 5 min at room temperature in the dark. Fluorescence of the samples was measured on a Molecular Devices SpectraMax M2e fluorescence plate reader using λ ex = 495 nm and λ em = 519 nm.
Kinase Assays. Kinase assay using recombinant active Akt1, Akt2, and Akt3. Kinase assay was performed with recombinant active Akt1, Akt2, and Akt3 proteins (Active Motif) using the nonradioactive Akt kinase assay kit (Cell Signaling) according to the manufacturer's protocol, with the following modifications. Akt1 and Akt2 proteins were oxidized or reduced with increasing concentrations of H 2 O 2 (25-500 μM) and DTT (10 μM to 1 mM), respectively, for 20 min at room temperature. This treatment was followed by incubation with the substrate GSK-3α/β in the presence of 0.4 mM each ATP and MgCl 2 for 10 min at room temperature. The kinase assay buffer used for these reactions was made fresh every time and lacked 1 mM DTT unlike the kinase assay buffer provided in the kit. At the end of the incubation period the reaction mixture was divided into two, and one set was quenched using 4× SDS sample buffer in presence of reducing agent β-mercaptoethanol, whereas the other set was quenched without the reducing agent. The samples under nonreducing conditions were subjected to immunoblotting with isoformspecific Akt1 and Akt2 antibodies, and the reduced set of reaction was probed for pGSK-3α/β(Ser9/12). The blots were stripped and reprobed for the substrate control using GST antibody. In a parallel experiment, recombinant active Akt1, Akt2, and Akt3 proteins were normalized to the same concentration of 0.35 μg/μL with Tris buffer (pH 7.5, containing 1 mM DTT). Normalized protein sample (1 μL) was added to either 19 μL of kinase assay buffer (control for non-H 2 O 2 treatment) or 18 μL of the kinase assay buffer plus 1 μL of 5 mM H 2 O 2 . The mixture was incubated for 20 min at room temperature. An aliquot of 3 μL mixture consisting of substrate GSK-3α/β, MgCl 2 (10 mM), and ATP (10 mM) (1 μL each) was added to each vial for further 10 min incubation. The reaction was quenched by adding 7 μL of 4× SDS sample buffer (plus β-mercaptoethanol) for SDS/PAGE and Western blot analysis. Blots were probed for p-GSK-3α/B (Ser9/12) and pAktT308/9 and reprobed for GST. Kinase assay using immunoprecipitated Akt proteins. After Akt1 and Akt2 immunoprecipitation the beads were washed once with 1× lysis buffer and twice with freshly prepared 1× kinase buffer lacking DTT, and kinase assay was performed according to the manufacturer's protocol with GSK-3α/β (1 μg, GST-linked) substrate in presence of 0.4 mM each ATP and MgCl 2 at 30°C for 30 min. For experiments that involved comparison of reaction kinetics under native and reducing conditions, tris(2-carboxyethyl)phosphine (TCEP; 1 mM) was added to the reaction mixture before addition of GSK-3α/β substrate. The resultant reaction mixture was separated on SDS/PAGE gels, transferred to nitrocellulose membrane, and probed for pGSK-3α/β(Ser9/12), pAktT308/9, GST, and Akt1 and Akt2 proteins (Cell Signaling antibody nos. 9327, 9275, 2625, 2967, and 3063).
Recovery of Akt2 activity by TCEP reduction after oxidation using recombinant purified Akt2 and Akt2 immunoprecipitated from fibroblasts.
Kinase activity assay was performed with recombinant active Akt2 protein (Active Motif) or with Akt2 immunoprecipitated from transfected NIH 3T3 fibroblasts pretreated with catalase inhibitor 3-AT using the Akt kinase assay kit (Cell Signaling) as described above. The active Akt2 protein was oxidized or reduced with H 2 O 2 (250 μM) and TCEP (1 mM, pH 7.0), respectively, for 20 min at room temperature. This treatment was followed by incubation with the substrate GSK-3α/β in the presence of 0.4 mM each ATP and MgCl 2 for 10 min at room temperature. To another set of Akt2 reaction, after treatment with H 2 O 2 (250 μM) for 20 min, TCEP (1 mM, pH 7.0) was added and incubated further for 10 min at room temperature. Endogenous Akt2 from untransfected and WT myr-Akt2 from transfected NIH 3T3 cells was immunoprecipitated using cross-linked Akt2 and V5 antibodies, respectively. TCEP (1 mM, pH 7.0) was added to the two Akt2 kinases after washes with kinase assay buffer and incubated for 10 min at room temperature just before addition of the substrate. At the end of the incubation period the reactions were terminated using 4× SDS sample buffer in presence of reducing agent β-mercaptoethanol. The resultant reaction mixture was separated on an SDS/PAGE gel, transferred to nitrocellulose membrane, and probed for pGSK-3α/β (Ser9/12), pAktT308/9, and GST proteins (Cell Signaling antibody nos. 9327, 9275, and 2625). Assessment of oxidation sensitivity of WT and Cys124Ser myr-Akt2. Human WT and Cys124Ser myr-Akt2 were transiently transfected in NIH 3T3 cells using a standard Lipofectamine 2000-based procedure (Invitrogen), and the transfectants were selected with blasticidin (6 μg/mL). The myr-Akt2 transfected cells were stimulated with PDGF-BB (20 ng/mL, 10 min), and the lysates were used to pull down WT and Cys124Ser myr-Akt2 proteins with V5 antibody conjugated to protein A-Sepharose beads. The endogenous Akt2 was immunoprecipitated from control, untransfected cells using Akt2 isoform-specific antibody. The immunoprecipitated WT and Cys124Ser myr-Akt2, along with endogenous Akt2, were subjected to in vitro oxidation with 100 μM H 2 O 2 for 20 min on a shaker at room temperature and assayed for kinase activity as described above. Similar procedures were followed to assess the sensitivity to oxidation of Cys297Ser and Cys311Ser myr-Akt2 mutants.
MS Experiments. Labeling of oxidized cysteines in Akt2 with dimedone and identification of labeled cysteines by MS. Recombinant active Akt2 (21 μM, supplied in Tris buffer containing 1 mM DTT) was treated with H 2 O 2 (1 mM) in the presence of dimedone (8 mM). The reaction was incubated at room temperature on a shaker for 1 h and terminated with 4× SDS sample buffer. The reaction mixture was subjected to SDS/PAGE, and the gel was stained with Gel Code Blue (Pierce). The protein bands were excised, and in-gel trypsin digestion was performed according to standard protocols. The resulting tryptic peptides were further separated and analyzed by nano-LC (Dionex Ultimate3000 System) coupled to a Thermo electrospray ionization linear trap quadrupole (ESI LTQ) mass spectrometer. A typical gradient was run for 60 min from 0 to 100% solvent B (80% ACN, 20% H 2 O, and 0.1% formic acid). Solvent A consisted of 5% ACN, 95% H 2 O, and 0.1% formic acid. The flow rate was set at 200 nL/min on a PepMap 100, C18, 3 μm, 100 Å, 75-μm i.d. × 15-cm column (Dionex; catalog no. 160321). The ESI LTQ mass spectrometer was operated in selected ion monitoring (SIM) mode for precursor ions corresponding to the peptides containing dimedonelabeled cysteine. The peptide identification was then performed automatically with the Bioworks 3.3 software. Dimedone labeling of Akt1 and Akt3. Six microliters of recombinant active Akt1 or Akt3 (0.28 μg/μL in Tris buffer containing 1 mM DTT, pH 7.5) was further diluted by adding 12 μL of 50 mM BisTris (pH 7.5), to which 1.6 μL of 0.1 M dimedone in DMSO was added, followed by addition of 0.6 μL of 20 mM H 2 O 2 . The labeling reaction was carried out at room temperature for l h with mixing. After labeling, Akt1 and Akt3 was in-gel digested with trypsin, and the extracted peptides were analyzed in data dependent or SIM mode by nano-LC-MS as decribed above.
Oxidation of active Akt2 for the identification of Cys124-Cys297 and Cys124-Cys311 intramolecular disulfides by MS. Recombinant active Akt2 stock (1.6 μL) (1.5 μg/μL in Tris buffer containing 1 mM DTT) was diluted in 7.4 μL of 50 mM Tris buffer (pH 7.5), and 1 μL of 10 mM H 2 O 2 was added to oxidize Akt2. After 1-h incubation at room temperature, the free thiols in Akt2 were alkylated by adding 1 μL of 0. Cells were lysed with the lysis buffer spiked with Akt2 protein in the presence of 200 μM DCP-Bio1, and the lysate was left on ice for 1 h. Lysis buffer containing the Akt2 protein with or without the DCP-Bio1 was also included as control. After incubation, cell debris was removed, and 15 μL of the supernatant was mixed with equal volume of 4× SDS sample buffer for SDS/PAGE and Western blot analysis. The membrane was probed for streptavidin-conjugated HRP. In another experiment, the SDS/PAGE gel was stained by Gel Code Blue to visualize proteins. For the immunoprecipitation experiment, 40 μL of the lysate was incubated with 10-μL agarose beads conjugated with anti-Akt2 antibody for overnight pulldown at 4°C. In the following day, the beads were washed by PBS and boiled in 40 μL of 4× SDS sample buffer to elute the proteins. The supernatant from the beads was then subjected to the SDS/PAGE and Western blot treatment. Biotinylated AhpC protein was included as positive control for the probe using streptavidin-conjugated HRP. The same membrane was stripped and reprobed for Akt2.
Glucose Uptake. Akt2 knockout MEFs transfected/transduced with WT and Cys124Ser myc-Akt2 were serum starved overnight in the presence or absence of 3-AT (10 mM). Next day, the cells were stimulated with PDGF (20 ng/mL) or insulin (200 nM) for 30 min along with the unstimulated cells as control. Medium was then removed, and cells were washed two times with 1× PBS at room temperature. The assay was initiated by the addition of 0.1 mM 2-deoxyglucose and 0.5 μCi/mL 2-deoxy-D-[ 
B.
A. GTPEYLAPEVLEDNDYGR. Notations for fragment ions are as follows: P*, one strand (Upper) of a dipeptide; p*, the other strand (Lower) of a dipeptide; capital letters, fragmentions from peptide P*; small letters, fragment ions from peptide p*; C-34, dehydroalanine ion; C+32, persulfide ion (formed by S-S or C-S bond cleavage reactions),^denotes phosphorylation site. DBond search parameters were precursor mass tolerance 2 Da, fragment ion mass tolerance 0.8 Da, and variable modifications: oxidation(M), phospho(ST), and carbamidomethyl(C). . Effect of PDGF, insulin, and TNF-α on oxidation and activity of Akt2 in C2C12 myoblasts vs. myotubes and the effect of WT and C124S Akt2 on signaling in Akt2 knockout MEFs. (A) Differentiated C2C12 myotubes were stimulated with PDGF, insulin, and TNF-α for 30 min followed by Akt2 pulldown from the normalized lysates for assaying activity using GSK-3α/β substrate in the presence and absence of incubation with TCEP (1 mM, pH 7.5). Akt2 activity increased significantly with TCEP treatment after PDGF and TNF-α treatment in the myotubes relative to insulin. Lower: DCP-Bio1-labeled lysates from C2C12 myotubes over a time course of TNF-α stimulation were captured with captavidin-agarose conjugate and probed for Akt2. TNF-α-dependent increase in DCPBio1 labeling was noted in the myotubes. (B) C2C12 myoblasts were stimulated with PDGF and Insulin for 30 min along with the unstimulated control, and Akt2 was immunoprecipitated for assaying activity using GSK-3α/β substrate in the presence and absence of incubation with TCEP (1 mM, pH 7.5). Akt2 activity increased significantly with TCEP treatment after PDGF and insulin treatment in the myoblasts. Lower: DCP-Bio1-labeled lysates from C2C12 myoblasts obtained after 5 and 30 min stimulation with PDGF and insulin were captured with captavidin-agarose conjugate and probed for Akt2. Both PDGF and insulin induced Akt2 oxidation in the myoblasts. 
